瑞士诺华的地拉罗司效果怎么样

A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of use in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of deferasirox is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d.

A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. According to the International Working Group's 2006 criteria, 51 patients (28%) had improved blood profiles, of which only 7 patients received growth factors or MDS.

Currently, the one most favored by patients is the one produced by Novartis in Switzerland. Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core businesses are in various patent medicines, consumer healthcare, generic medicines, eye care and animal health. According to Medical Companion Travel, the specification of Deferasirox from Novartis Switzerland is 400mg*30 tablets, but the price is only 420$, which is more suitable for patients for long-term use. Since the exchange rate is not static, the price will also fluctuate. For details, please consult Medical Companion Travel.

Recommended related hot articles: /newsDetail/94088.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.